Russ Conroy

Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.

Updated results from the phase 1 CK-301-101 trial support the updated label for cosibelimab in this cutaneous squamous cell carcinoma population.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Investigators are currently assessing the safety and preliminary activity of AVZO-103 among patients with advanced solid tumors in a phase 1/2 trial.

One patient with newly diagnosed glioblastoma multiforme reached 3 years of survival following treatment with temferon in a phase 1/2a trial.

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Data from a phase 1/2 trial demonstrate the potential antitumor activity of FOG-001 in patients with desmoid tumors.

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Preliminary findings from a phase 2 trial show clinical activity with MB-105 in patients with relapsed/refractory T-cell lymphoma.

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

Phase 2 data show consistent overall immunotherapy immunogenicity with ELI-002 7P in those with KRAS-mutated pancreatic ductal adenocarcinoma.

Data from the ASCENT-07 trial show an early trend toward improved overall survival with sacituzumab govitecan vs chemotherapy.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Data from the phase 2 INTERACT-ION trial support further investigation of the potential synergistic effect of ezabenlimab plus adaptive chemoradiotherapy.

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable to prior reports of each individual agent.

Data from the phase 3 AQUILA study support the FDA approval of subcutaneous daratumumab in this population with smoldering multiple myeloma.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.